Citigroup’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-332,300
| Closed | -$38K | – | 7952 |
|
|
2018
Q4 | $38K | Sell |
332,300
-357,000
| -52% | -$234K | ﹤0.01% | 6468 |
|
|
2018
Q3 | $1.17M | Buy |
689,300
+6,400
| +0.9% | +$11.5K | ﹤0.01% | 3312 |
|
|
2018
Q2 | $1.19M | Buy |
682,900
+68,500
| +11% | +$118K | ﹤0.01% | 3171 |
|
|
2018
Q1 | $1.12M | Buy |
614,400
+219,200
| +55% | +$463K | ﹤0.01% | 3134 |
|
|
2017
Q4 | $881K | Buy |
395,200
+254,200
| +180% | +$632K | ﹤0.01% | 3465 |
|
|
2017
Q3 | $409K | Sell |
141,000
-10,200
| -7% | -$34.8K | ﹤0.01% | 4317 |
|
|
2017
Q2 | $673K | Buy |
151,200
+47,700
| +46% | +$197K | ﹤0.01% | 3714 |
|
|
2017
Q1 | $482K | Buy |
103,500
+25,300
| +32% | +$147K | ﹤0.01% | 3898 |
|
|
2016
Q4 | $476K | Buy |
78,200
+8,900
| +13% | +$46.5K | ﹤0.01% | 4423 |
|
|
2016
Q3 | $382K | Buy |
69,300
+1,600
| +2% | +$7.49K | ﹤0.01% | 4138 |
|
|
2016
Q2 | $257K | Buy |
67,700
+30,100
| +80% | +$102K | ﹤0.01% | 4271 |
|
|
2016
Q1 | $104K | Buy |
37,600
+34,900
| +1,293% | +$126K | ﹤0.01% | 5640 |
|
|
2015
Q4 | $15K | Buy |
2,700
+1,800
| +200% | +$11K | ﹤0.01% | 6638 |
|
|
2015
Q3 | $5K | Buy |
+900
| New | +$6.96K | ﹤0.01% | 6775 |
|
Other funds holding SGYP
Citigroup's SGYP Position: Q1 2019 in Review
Citigroup sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 716,402 shares — an estimated $82K sold.
Citigroup first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $5.21M in Q4 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.
- Citigroup reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
- Citigroup sold 716,402 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $82K.
- Citigroup first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
- Citigroup's Synergy Pharmaceuticals, Inc Common Stock position peaked at $5.21M in Q4 2017.
- 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.
Based on Citigroup's 13F filing for Q1 2019, filed 13 May 2019.